Key Takeaways

Key players operating in the Recombinant Protein Market are Merck KGaA, Allergan plc ( A subsidiary of AbbVie Inc.), Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical (A subsidiary of Alcon Management S. A) and Mylan N.V (A subsidiary of Viatris Inc.). These players are focusing on innovating new gene expression technologies to reduce production costs and time.

The market provides numerous opportunities for key players in the form of investment in new production facilities, acquisitions and collaboration with research institutions. Growing applications of recombinant proteins in chronic disease management, vaccine development and other therapeutic areas is expected to drive the Recombinant Protein Market Share.

Advancements in gene expression technologies like cell-free protein synthesis help simplify protein production without the need to culture and harvest live cells. This paves way for sustainable and versatile production methods.

Market drivers

Increasing incidence of chronic diseases globally is the major factor driving the demand for effective therapeutic proteins. Recombinant proteins have emerged as an attractive alternative to conventional proteins owing to greater safety, efficacy and standardization. Advancements in healthcare infrastructure and diagnosis have boosted the adoption of recombinant proteins. Growing biologics industry is anticipated to positively impact the recombinant protein market. Increased RD investments by both public and private players for developing novel therapeutics will further fuel the market growth over the forecast period.

Current Challenges in the Recombinant Protein Market
The recombinant protein market is facing certain challenges which are hindering its growth. Stringent regulatory norms associated with recombinant protein production is a major issue as any adverse event can delay the approval process. Safety and efficacy of recombinant proteins need to be thoroughly established before approval and commercialization. Ensuring consistent quality and reducing batch-to-batch variability during manufacturing is also difficult. Developing economically viable production processes to produce recombinant proteins on a commercial scale poses technical challenges. Dependence on mammalian cell cultures increases production costs significantly. Patient non-compliance with medication due to complex dosage regimens prescribed for certain recombinant proteins can impact long-term effectiveness.

Get more insights on Recombinant Protein Market